glp-1 receptor agonist patient assistance programs Agonists and Other Drugs Emerging Evidence Positions GLP-1 Receptor

Generic semaglutide starts from 325 per weekly injection, branded Ozempic (Novo Nordisk) from 1,415 per weekly injection

The choice between metformin and GLP-1s, or any other blood sugar lowering medication, should be made based on individual factors, including the patient's medical history, lifestyle, treatment goals, and potential side effects

Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X, et al

While these treatments remain in various stages of development, they highlight the growing recognition that novel, mechanism-driven therapies are needed to address addiction effectively

Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice

Key Takeaways In 2024, the market for GLP-1 receptor agonist generated a revenue of US$ 53.5 billion , with a CAGR of 17.5% , and is expected to reach US$ 268.4 billion by the year 2033